Mountain Valley MD proceeds with pre-clinical cancer trials and files a related cancer patent
The company said ivectosol is being tested to target certain cancers to pursue novel human intratumoral injection and intravenous infusion The firm said its “solubility technology” applied to the ivermectin drug uses “excipients that are approved by the FDA making it a leading candidate for human injection or intravenous infusion
Mountain Valley MD Holdings Inc (CSE:MVMD) (FRA:20MP) (OTCQB:MVMDF) announced that the company has filed a novel cancer adjuvant patent and is proceeding with pre-clinical trials with third-party cancer Contract Research Organizations (CROs) in triple-negative breast cancer, metastatic melanoma, and lung carcinoma.